Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

saudi arabian japanese pharmaceutical co. ltd., saudi arabia - solution - 18 mg - aspartame

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

saudi arabian japanese pharmaceutical co. ltd., saudi arabia - solution - 18 mg - aspartame

Singapore - English - HSA (Health Sciences Authority)

santen pharmaceutical asia pte. ltd. - ophthalmology - eye drops for treatment and prevention of allergic conjunctivitis symptoms.

Singapore - English - HSA (Health Sciences Authority)

santen pharmaceutical asia pte. ltd. - ophthalmology - eye drops for treatment and prevention of dry eyes symptoms.

Singapore - English - HSA (Health Sciences Authority)

santen pharmaceutical asia pte. ltd. - ophthalmology - eye drops for treatment and prevention of dry eyes symptoms.

United States - English - NLM (National Library of Medicine)

tianjin tianyao pharmaceuticals co., ltd. - celecoxib (unii: jcx84q7j1l) (celecoxib - unii:jcx84q7j1l) - celecoxib capsules is indicated for the management of the signs and symptoms of oa [see clinical studies (14.1) ] for the management of the signs and symptoms of ra [see clinical studies (14.2) ] for the management of the signs and symptoms of jra in patients 2 years and older [see clinical studies (14.3) ] for the management of the signs and symptoms of as [see clinical studies (14.4) ] for the management of acute pain in adults [see clinical studies (14.5) ] for the management of primary dysmenorrhea [see clinical studies (14.5) ] celecoxib is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see warnings and precautions (5.7, 5.9) ]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids, have been reported in such patients [see warnings and precautions (5.7, 5.8) ]. - in the se

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dksh malaysia sdn. bhd. - ripasudil hydrochloride hydrate -

United States - English - NLM (National Library of Medicine)

cspc ouyi pharmaceutical co. ltd - levamlodipine maleate (unii: 12ww9t2ita) (levamlodipine - unii:0p6nlp6806) - conjupri® is indicated for the treatment of hypertension in adults and patients 6 years and older, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including levamlodipine. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of phar

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

prince pharmaceuticals co.ltd, tanzania - gel - 96 %v/v

United States - English - NLM (National Library of Medicine)

cisen pharmaceutical co., ltd. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - adults esomeprazole magnesium delayed-release capsules is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of nexium may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules is indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age. esomeprazole magnesium delayed-release capsules is indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules is indicated for short-term treatment (4